

From: Tazia Smith <[REDACTED]>
To: jeevacation@gmail.com
Cc: Nav Gupta <[REDACTED]>, Paul Morris <[REDACTED]>, [REDACTED], Vahe Stepanian <[REDACTED]>, Vinit Sahni <[REDACTED]>
Subject: Re: Biotech Update... Gilead beat, shares halted [C]
Date: Tue, 22 Apr 2014 20:16:17 +0000
Inline-Images: unnamed; unnamed(1); unnamed(2); unnamed(3); unnamed(4); unnamed(5); unnamed(6); unnamed(7)

Classification: Confidential

Jeffrey - sure you see this, just making sure, Gilead shares are halted in the after-market following a significant top and bottom-line earnings beat (\$1.48 vs \$0.92 cons eps, \$5bn on the topline vs. expectations of \$3.96bn) as you know, you're long 8100 shares at an average price of \$79.41, stock closed today at \$72.86, just reported.

Shares expected to re-open at 4:30pm



From: Tazia Smith <[REDACTED]>
To: jeevacation@gmail.com,
Cc: Paul Morris, Vahe Stepanian/db/[REDACTED], Nav Gupta/[REDACTED], Vinit Sahni/[REDACTED], [REDACTED]
Date: 04/02/2014 03:42 PM
Subject: Biotech Update... [C]

Classification: Confidential

Jeffrey -

Biotech forming a base to some extent (strong market backdrop, clearly) - you're up \$906k on your basket excluding the Ariad (outlier due to M&A prospects vs. group drivers) 1-mo price history charts below.

As of 4/2/14 3:27 pm							
Description	Trade Date	Quantity	Current Price	Unit Cost	Market Value	Current Total Cost	Unrealized G/L
SANGAMO BIOSCIENCES	5/28/2013	50,000.00	\$ 17.51	\$ 8.44	\$ 875,500.00	422,214.00	\$ 453,286.00
BIOGEN	2/14/2012	2,095.00	\$ 308.71	\$ 119.55	\$ 646,747.45	250,454.95	\$ 396,292.50
FOUNDATION MEDICINE	1/13/2014	25,000.00	\$ 31.62	\$ 27.51	\$ 790,500.00	687,663.50	\$ 102,836.50
GILEAD SCIENCES INC	Multiple	8,100.00	\$ 73.79	\$ 79.41	\$ 597,699.00	643,204.00	\$ (45,505.00)
				Total Biotech	\$ 3,043,139.83	\$ 2,294,533.85	\$ 906,910.00
ARIAD PHARMACEUTICALS	Multiple	16,535.00	\$ 8.03	\$ 17.60	\$ 132,693.38	290,997.40	\$ (158,304.03)

SGMO 1mo Price History



BIIB 1mo Price History



GILD 1mo Price History



FMI 1mo Price History



Tazia Smith
 Director | Key Client Partners - US

DB Securities Inc

Passion to Perform

This communication may contain confidential and/or privileged information. If you are not the intended recipient (or have received this communication in error) please notify the sender immediately and destroy this communication. Any unauthorized copying, disclosure or distribution of the material in this communication is strictly forbidden.

Deutsche Bank does not render legal or tax advice, and the information contained in this communication should not be regarded as such.